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Abstract: 
Background Polycystic ovary syndrome is one of well-known disorder that affects females during their 
reproductive period. The etiology and the pathogenesis of this disorder are still unclear since many scientists 
consider some factors are the causes of this disorder while the others proved them as a result of this disorder. 
In general, this disorder chaptalized mainly by hormonal imbalance which reflected itself as pathological 
changes which mainly summarized by multiple large cysts associated with clinical features mainly disturbance 
of menstruation and infertility.  
Two parameters play a principal role in pathogenesis and a guide line in the progression of the treatment. These 
are aromatase enzyme activity and estrogen receptor B distribution. 
Now a day many lines of treatment are involved in the treatment of polycystic ovary syndrome, but the two 
important one are the use of antihyperinsulinemic drugs (like metformin) and aromatase inhibitors (like 
anastrozole). 
The aim of this research is to study the mode of action of these two drugs through using immunohistochemical 
techniques and illustrate their effect on aromatase enzyme activity and estrogen receptor B distribution in 
different ovarian tissues. 
Materials and methods: Twenty-six premature female Norway albino rats aged 21 day had been involved in 
this study. Five of them considered as controls while the others received testosterone for 4 weeks to induce 
polycystic ovary and considered as experimental group. The experimental group divided into 3 subgroups, the 
first one received nothing while the second one was treated with metformin and the third one was treated with 
anastrozole. In all the groups, the aromatase enzyme activity and estrogen receptor B distribution had been 
examined through using immunohistochemical technique. 
Result: The results revealed improvement in the syndrome reflected through increase in the activity of 
aromatase enzyme besides increase in the estrogen receptor B distribution in certain ovarian tissues. However 
the intensity of aromatase activity and the intensity of estrogen receptor expression varied according to the 
treatment used. 
Discussion:  Both drugs, used in the treatment of polycystic ovary syndrome, were act through normalization of 
the sexual hormonal situation in order to preserve the normal histology and the physiological function of the 
ovary. However, anastrozole proved to be much better as a therapy than metformin in this line.     
              
1. Introduction 
Polycystic ovary syndrome (PCOS) is considered to be one of the common endocrine disorder that the females 
suffer from during their reproductive period of life (Aziz et al, 2004). The syndrome called so since the ovaries 
have multiple cortical cysts distorting their smooth outline (The Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004). It affects about 28% of obese women and about 5% of non-obese ones 
(March et al, 2010). 
The etiology of this disorder is still not clear since so many factors integrat in its development 
(Ehrmann, 2005). Although, many factors could be shared in PCOS etiology, like hyperinsulinemia (Venkatesan 
et al, 2001), hormonal imbalance (Marx and Metha, 2003), chronic inflammatory process (Repaci et al, 2011) 
and other causes, yet, some of these etiological factors could be considered as consequences of PCOS rather than 
its causes. 
The diagnosis of PCOS is controversial as its etiology, since many criteria were considered by the 
endocrinologists and the gynecologists for making a diagnosis. However, whatever the character of these 
diagnostic criteria, the principle factors shared among them are the disturbance of sex hormones that leads to 
infertility, menstrual disturbances besides other systemic symptoms (Azziz et al, 2004). This hormonal 
disturbance results in the distortion of the normal physiological cycle between the pituitary gland and the ovaries 
through feedback mechanism (Guyton and Hall, 2010). One of the crucial steps in this cycle is mediated by 
aromatase enzyme (Diamanti-Kandarakis, 2008). 
 Aromatase is the microsomal cytochrome P450 enzyme that function is the conversion of androgen to 
estrogen (Cole & Robinson, 1990). The activity of aromatase enzyme could be detected in many normal tissues, 
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mainly the ovaries, brain, adipose tissue, muscles, liver, besides abnormal tissues like breast cancer (Nelson and 
Bulun, 2001). The main source of estrogen in premenopausal period is the ovary, while during the 
postmenopausal period the fatty tissue is the first line in estrogen production (Santen et al, 1990). Regarding the 
distribution of aromatase enzyme in the ovary, it is varied between its different tissues and changing during the 
different developmental stages of the ovary during menstrual cycle (Stocco, 2008).  
Another line that one has to search for to understand the pathogenesis and to follow up the course of 
the treatment of PCOS, is estrogen receptors. These receptors are groups of proteins spread intracellularly and 
activated by estrogen (Hosokawa et al, 2001). They are present in different tissue and organs in the body, yet, the 
ovaries being the first site among other organs in expressing estrogen receptors (Taylor and Al-Azzawi, 2000).  
Estrogen receptors are of two types: estrogen receptors alpha (ERα) and estrogen receptors beta (ERβ). 
The most important type, regarding its role in ovarian function, is ERβ which is present in the granulosa cells, 
theca interna cells, and corpus luteum (Drummond and Fuller, 2012). On the other hand, ERα is present mainly 
in the ovarian stroma (Sánchez-Criado et al, 2005). 
The treatment of PCOS includes many lines, one of them is the use of antihyperinsulinemic agents 
(like metformin). Another line of PCOS treatment is the recent use of aromatase inhibitors (like anastrozole) to 
induce ovulation, instead of the old approach of using clomiphene citrate (which is estrogen receptor blocker) 
due to the unwanted side effects of the latter (Kamat et al, 2002). The mode of action of these two agents 
(metformin and anastrozole) in PCOS treatment is quite different. 
 
2. Aim of the study 
A trial to study the mode of action of metformin and aromatase inhibitors (in this study,  anastrozole) in PCOS, 
using immunohistochemical technique to study the activity of aromatase enzyme and the intensity of distribution 
of estrogen receptors B within various ovarian tissues and cells in the induced PCOS female rat model when 
these two therapeutic agents had been used.   
 
1. Materials and Methods 
The experimental animals used in this study were Norway albino rats that were kept under optimal conditions 
throughout the study. Six mature males and six mature females were kept as pairs in isolated cages. After mating 
and pregnancy period, the males were separated from the pregnant females before delivery. The pregnancy 
outcome of the six dams was 36 pups; including 28 females and 8 males. Two female pups died during the first 
postnatal week, and the remaining 26 female pups were left with their mothers till the age of 21 days, they were 
divided into 4 groups and started to have specific treatment as shown in table 1. 
 
Regarding the experimental groups, the rats received 1 mg/100 g of body weight/day of testosterone 
propionate (TP) (Sustanon 250 mg/1 ml ampoule, N.V. Organon OSS Holland) daily for 4 weeks. Testosterone 
propionate had been given by subcutaneous injection at the back of the neck of the premature female rats 
(Walters et al, 2012). 
All the animals (control and experimental groups) had been exposed in the last week of treatment to 
daily vaginal smears, and accordingly, animal sacrifice had been done during proestrous phase of estrous cycle 
(Goldman et al, 2007). 
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After anaesthesia, perfusion fixation had been performed, then the ovaries had been excised. Then the 
fatty tissue surrounding the ovary was removed and then the ovaries were paraffinized, sectioned at 5-6 µm thick 
sections and prepared for immunohistochemical study. 
The immunohistochemical study of the ovaries had been performed to investigate two important parameters: 
1. Aromatase enzyme (P450arom) activity. 
2. Estrogen receptor beta (ERβ) distribution intensity. 
To achieve these studies, streptavidin-biotin (LSAB) complex method had been used to utilize the extraordinary 
affinity of streptavidin for biotin (Chilkoti et al, 1995), using anti-aromatase antibody and anti-estrogen receptor 
beta antibody, respectively. The following ovarian tissues and cells that had been studied for the 
immunoreactivity of aromatase enzyme activity and the distribution of ERβ were: 
- Granulosa cells of primary, secondary and mature follicles, 
- Corpora lutea, 
- Theca interna cells of secondary and mature follicles ,  
- Granulosa cells in the wall of large cystic follicles, 
- Interstitial glands. 
Positive immunoreactivity for both parameters was detected by brownish discolouration of the investigated 
tissues and cells. The intensity of immunohistochemical reaction was scored using semiquantitative 
immunohistochemical scoring method (Tyndall et al, 2012) for both parameters, as demonstrated in table-2. 
 
4. Results 
The results obtained in this study after performing the immunohistochemical techniques can be divided into two 
sets: the activity of aromatase enzyme within the ovarian tissues, and the intensity of estrogen receptor B 
ditribution within the ovarian tissues. 
a. The activity of aromatase enzyme: 
• Control group: aromatase activity was strongly evident in the granulosa cells of the large antral and 
mature follicles, and was more clear in the mural granulosa cells. Granulosa cells of the primary 
follicles revealed weak reactivity. Moderate reaction was demonstrated by corpora lutea cells, Theca 
cells and interstitial glands revealed negative enzyme reaction (Fig.1-A). 
• TP-treated subgroup: primary and secondary/mature follicular granulosa cells revealed weak 
immunoreactivity. However, enzymatic activity in primary follicular theca cells was relatively stronger 
than those of the control group. About half of the cells in the wall of large cysts revealed moderate 
immunoreactivity. No reaction could be illustrated in corpora lutea since no corpora lutea had been 
developed in this group. Theca cells and interstitial glands had weak immunoreactivity (Fig 1-B). 
• MET-treated subgroup: about 40% of granulosa cells of secondary/mature follicles elicited moderate 
enzymatic reaction, while cells of the primary follicles showed weak reaction. Corpora lutea, although 
detected in almost half of the animals in this group, revealed weak activity. Theca cells and interstitial 
glands revealed no reactivity (Fig.1-C) 
• ANA-treated subgroup: 80% of granulosa cells in the primary and secondary/mature follicles revealed 
moderate enzymatic immunoreactivity, while cells in the wall of large cysts stained weakly (i.e. weak 
enzymatic activity). Regarding corpora lutea, the same intensity of enzymatic reaction and percentage 
of cells involved, could be detected as that of the granulosa cells of antral/mature follicles. Theca cells 
and interstitial glands showed no enzymatic activity (Fig.1-D). 
 
b. The intensity  of ERβ distribution: 
• Control group: the estrogen receptors beta in the ovaries of this group revealed their strongest 
distribution (the strongest immunoreactivity) in the granulosa cells of the antral/mature follicles. Strong 
ERβ reactivity could be detected in the theca cells, while the primary follicles revealed weak reactivity. 
Corpora lutea illustrated moderate uneven distribution of immunoreactivity within their cells. Interstitial 
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glands showed strong immunoreactivity to ERβ. 
• TP-treated subgroup: moderate receptor distribution could be demonstrated in the granulosa cells of 
primary and secondary follicles, while 30% of theca cells revealed strong immunoreactivity. No 
reaction could be demonstrated within corpora lutea since no corpus luteum was developed in the 
ovaries of this group. The interstitial cells had the strongest immunoreactivity among all ovarian cells 
and tissues of this group. 
• MET-treated subgroup: granulosa cells of antral/mature follicles showed moderate- strong 
immunoreactivity to ERβ, while the cells of the primary follicles had a weak receptor distribution. Less 
than half of theca cells revealed weak reaction. Moderate immunoreactivity could be illustrated in the  
 
5. Discussion 
The philosophy behind the treatment of PCOS, whatever the line of treatment used, is to restore the normal 
physiological sex hormones cycle between the ovary and pituitary gland. This is the aim of the different PCOS 
treatment approaches whatever their different modes of action. 
One of the main PCOS treatment lines is the antihyperinsulinemic therapy (metformin). Metformin 
could act locally on the ovary (Attia et al, 2001; Mansfield et al, 2003), and systematically through its 
antihyperinsulinemic effect (Ehrmann, 2005). Both of these mechanisms can lead to a reduction in the ovarian 
production of androgens & improve the state of hyperandrogenemia that characterizes PCOS. Reduction in 
androgen levels can correct its feedback inhibitory effect on the pituitary gland, resuming –to a certain degree- 
the production of sufficient amounts of FSH and LH necessary to restore the normal ovarian function(John E 
Hall 2011). This increase in the level of FSH& LH will stimulate aromatase enzyme to convert the endogenous 
androgen into estrogen(Merlotti et al2011). Although this metformin-mediated improvement in gonadotropin 
(FSH) secretion is still subnormal, it appears to be able to induce the growth of some primary and secondary 
follicles to mature follicles with some increase in aromatase activity in their theca cells. On the other hand, LH 
secretion improvement after metformin treatment, is still below the normal level to restore normal ovulation, as 
evident by the small (less than half) number of animals which could ovulate & subsequently developed corpora 
lutea with weak aromatase immunoreactivity in this subgroup. 
Regarding anastrozole treatment, the results obtained were almost similar to those of the normal 
(control) ovary. Anastrozole is an inhibitor of aromatase enzyme, it prevents the aromatization of androgens into 
estrogen in the ovary, reducing the amount of estrogen produced by the ovary. This reduction is believed to 
stimulate the anterior pituitary gland to secrete higher amounts of FSH and LH via negative feedback mechanism. 
This will stimulate aromatase enzyme to convert androgen into estrogen hormone (Barett et al 2010) which, in 
turn, acts to stimulate the maturation of ovarian follicles and induce ovulation, respectively. This explains its 
high expression  of aromatase enzyme in the mature follicles of this subgroup. Besides, resumption of LH surge 
is evident by the resumption of ovulatory function of the ovary (Mescher 2013), as revealed by the large number 
of corpora leutea seen in all of the ovaries of this group of animals, with the increment in aromatase activity in 
the cells of those corpora leutea.   
Regarding estrogen receptor beta distribution, it is well known that the site where estrogen could 
express its action is estrogen receptor. Therefore, wherever estrogen is needed, estrogen receptors are present 
and the intensity of distribution goes parallel with the estrogen need of the different ovarian tissues (Kurl and 
Morris 1978). According to this concept, the map of ERβ distribution within ovarian tissues, which was 
demonstrated through using immunohistochemical technique in this study, could be understood. 
The control group revealed weak activity in the primary follicles, while the granulosa cells of the 
mature follicles elicited the strongest of ERβ immunoreactivity among the ovarian tissues. This agrees with the 
previous hypothesis since the follicle needs the highest concentration of estrogen for maturation and formation of 
the graafian follicle (Hall 2011), this has illustrated itself as a strong intensity of immunoreactivity (reflecting 
high intensity of ERβ) in the granulosa cells of the mature follicles. On the other hand the primary follicles, 
which have started the process of maturation, revealed weak activity. Corpus luteum revealed uneven moderate 
activity, which could be explained by the fact that the granulosa cells of the mature follicle that remain after 
ovulation, are responsible for this result.  
Regarding TP-treated subgroup, the aromatase enzyme converts androgen into estrogen under the 
umbel of FSH action (Diamanti-Kandarakis, 2008). However, this conversion is more than need of ovarian 
tissues, which leads to negative feedback mechanism preventing FSH secretion by the pituitary gland, which in 
turn reduces the endogenous estrogen production (Hall 2011), reflected as a minimal ERβ distribution. 
Accordingly, the results of ERβ distribution in TP-treated subgroup had been illustrated as mentioned in this 
study. Since the negative feedback mechanism would reduce FSH secretion from the pituitary gland, no mature 
graafian follicle could be found, and failure of ovulation will occur, evidenced by the absence of corpora lutea in 
the ovaries of this group (Sadler 2012   ). Although negative feedback mechanism of hormonal secretion from 
the pituitary gland will be established, yet small amounts of estrogen was still present in the circulation, and 
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limited number of ERβ were present, which illustrated themselves as a moderate immunoreactivity in the 
primary and secondary follicles.  
 
 
 
 
Figure 1: Aromatase enzyme activities in the different ovarian tissue in the studied groups; (A) 
control group,           (B) TP-treated subgroup, (C) MET-treated subgroup, & (D) ANA-treated 
subgroup. TI: theca interna, GC: granulosa cells, CL: corpus luteum, C: cyst wall, 1ºF: primary 
follicle, 2ºF: secondary follicle, arrow: primary follicular cells (in MET-treated subgroup). 
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The distribution of ERβ in MET-treated subgroup and ANA-treated subgroup will be discussed 
together to match the aim of this study. The results revealed an obvious difference in ERβ distribution between 
these two subgroups, which could be attributed to the different modes of action of the treatment lines used in 
each subgroup.  
Starting with MET-treated subgroup, as mentioned above, metformin is known to act locally (Attia et 
al, 2001; Mansfield et al, 2003), and systematically (Ehrmann, 2005) to reduce androgen synthesis by the theca 
cells, and hence, reduces estrogen production temporarily since androgen conversion into estrogen will be 
reduced (Cole and Robinson, 1990). This mechanism will stimulate the pituitary gland (through feedback 
mechanism) to resume its normal physiological secretion of gonadotropins, mainly FSH. FSH, which restore 
follicular maturation and estrogen production by the granulosa cells, will resume the normal physiological 
function of the ovary (Hall 2011). Besides, FSH induces a cofactor that coactivates ERβ in granulosa cells 
Corpora lutea, which were seen in almost half of the animals in this subgroup. The cells 
of interstitial glands showed a strong immunoreactivity(Fig.2- A & B). 
• ANA-treated subgroup: granulosa cells of the primary and secondary/mature follicles in 
this subgroup showed moderate immunoreactivity, while theca cells revealed strong 
receptor distribution. All of the animals in this subgroup showed well developed corpora 
lutea, which demonstrated strong immune-histochemical reactivity in their cells. The 
interstitial glands demonstrated an intense distribution of ERβ (Fig.2- C & D). 
Figure 2: Estrogen receptor beta distribution in MET-treated group (A & B) and ANA-treated 
group (C & D).         TI: theca interna, GC: granulosa cells, IG: interstitial glands, CL: corpus 
luteum, 1ºF: primary follicle, 2ºF: secondary follicle. 
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(Cheng et al, 2002). Accordingly, the intensity of ERβ distribution that has been demonstrated using 
immunohistochemical methods, will be decided. However, this process of metformin-mediated hormonal 
normalization appears to be still suboptimal, i.e: metformin could not restore the physiological levels of sex 
hormones to the normal level, since prevention of hyperandrogenemia could be still subnormal. This was 
reflected clearly by deficiency in immunohistochemical reactivity regarding the distribution of ERβ and its 
intensity in different ovarian tissues, obviously seen in corpus luteum which was only detected in less than half 
of the animals, reflecting ovulatory failure in more than half of female animals in this subgroup.  
Regarding ANA-treated subgroup, anastrozole is an aromatase enzyme inhibitor that acts by 
preventing the aromatization of androgens to estrogens. This leads to a reduction in estrogen level produced by 
conversion of androgen into estrogen in the ovarian follicles. The reduction in estrogen levels stimulates the 
pituitary gland to secrete more FSH and LH. The increased FSH level will stimulate the aromatization of the 
androgen in theca cells into estrogen (Barett et al, 2010), which appears to be enough to restore the follicular 
growth and maturation. The higher amount of LH secreted from the pituitary gland then induces ovulation in 
many mature follicles and resume normal maturation of corpora leutea, resuming the ovarian physiology to 
almost normal state. This is reflected by the results obtained in this subgroup via the immunohistochemical 
technique. According to the concept mentioned in the beginning of this discussion, since estrogen hormone is 
present, and the ovarian tissues that need estrogen could be detected, therefore ERβ distribution and intensity 
could be illustrated as had been shown in ANA-treated subgroup in this study. Besides, the sign indicating that 
anastrozole restored ovarian function near normal level is the resumption of ovulation: this study has 
demonstrated that all of the experimental animals treated with anastrozole have developed large corpora lutea, a 
definitive sign of ovulation (Sadler 2012). 
To summarized the conclusion, PCOS therapy, specifically the medications used in this study 
(metformin and anastrozole), acts to standardize the ovary to restor its normal physiological function, whatever 
the mode of their action. In sequence this will preserve the normal physiological sexual hormonal cycle between 
the ovary and the pituitary gland leading to normal physiological function of the ovary, regarding maturation of 
the follicle and ovulation.                                            
In this study, anastrozole proved to be superior in returning the ovary to its normal physiology than 
metformin did.   
 
Recommendation: 
To make the results and discussion solid enough, it is recommended to do hormonal assay including estrogen, 
FSH, LH and androgen in each subgroups received the different therapies. 
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